China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced a strategic collaboration with US firm UroViu Corporation, obtaining exclusive global rights to UroViu’s patented portable single-use cystoscope in the field of fluorescent imaging.
Combining Technology for Non-Muscle Invasive Bladder Cancer (NMIBC) Research
Under the agreement, Asieris will utilize this patented technology in conjunction with specific optical imaging agents to conduct research on the application of non-white light imaging technology in the diagnosis and postoperative monitoring of non-muscle invasive bladder cancer (NMIBC). This collaboration aims to enhance the detection and surveillance of NMIBC, a critical area in urogenital oncology.
Global Commercialization of Sterile Single-Use Fluorescent Cystoscope
Asieris will also be responsible for the global commercialization of the sterile single-use fluorescent cystoscope. This follows a previous cooperation agreement between Asieris and UroViu in 2021, which granted Asieris exclusive registration and commercialization rights to UroViu’s portable single-use flexible white light cystoscopy system in mainland China, Taiwan, Hong Kong, and Macau.
UroViu’s Proprietary Endoscopic Platform and FDA Approvals
UroViu has developed a proprietary, portable single-use endoscopic platform of minimally invasive devices designed to address issues of device cross contaminations, patient discomfort, and workflow inefficiencies. From this platform, UroViu has already received four FDA approvals for urology and gynecology indications, highlighting the company’s commitment to innovation in minimally invasive medical devices.-Fineline Info & Tech
